Oncoshot and MSK Innovation Hub (iHub) Launch Global Clinical Data Collaboration to Advance Cancer Research Across Diverse Populations

NEW YORK and SINGAPORE – 2nd April 2026 – Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment institution in the United States conducting more than 900 clinical studies annually, and Oncoshot, a pan–Asia Pacific (APAC) AI-powered oncology research collaboration platform with hospital partners across Singapore, India, Japan, and Australia, have signed a Collaboration Agreement with the MSK Innovation Hub (iHub) to explore and potentially extend the use of MSK’s Core Clinical Data Elements (CCDE) data model to Oncoshot's APAC partners.

This collaboration will enable future alignment of MSK's established clinical data framework with Oncoshot's regional network, creating new shared clinical research capabilities between MSK and leading public/private cancer centers in the Asia-Pacific region. By adopting a unified data model within Oncoshot's secure, federated real-time LLM-based data extraction systems, investigators at MSK and Oncoshot partner institutions will be able to harmonize data capture, accelerate study start-up, and promote interoperable evidence generation across multiple international sites.

Asia-Pacific is home to some of the world's most innovative cancer centers, treating diverse patient populations and generating valuable clinical insights. However, the region's hospitals have historically faced barriers to participating in cutting-edge international research due to fragmented data standards. This collaboration changes research dynamics by leveraging AI to standardize data to MSK's CCDE model, enabling APAC hospitals to access collaboration opportunities with one of the world's premier cancer research institutions and improving access to innovative cancer treatments for patients.

Strategic Vision of the Collaboration

The collaboration is the first step towards achieving key strategic goals aimed at accelerating global oncology research and clinical care.

Standardized Clinical Data Sharing – Dissemination of MSK's proven CCDE data model across Oncoshot's APAC network could create a common language for clinical research, enabling seamless data harmonization without compromising local governance or patient privacy.

Enhanced Cross-Border Research – The partnership creates an unprecedented dynamic research ecosystem connecting leading cancer centers across continents, facilitating multi-site studies that could draw on diverse patient populations supporting industry regulatory submissions and investigator-initiated studies.

Diverse, Global Evidence Generation – By bridging public and private institutions across four major APAC markets, the collaboration may potentially enable large-scale, diverse-population research that ensures clinical evidence reflects the full spectrum of global patient demographics and disease profiles.

Improved Cancer Outcomes within Partner Network – Knowledge exchange between regional institutions and MSK's research community can drive potential improvements in cancer care and outcomes for patients throughout the partner network.

Partner Perspectives

"Partnering with MSK to adopt the Core Clinical Data Element (CCDE) data model across our APAC partner hospitals strengthens our shared mission to advance oncology research," said Dr. Huren Sivaraj, CEO and Co-founder, Oncoshot. "This agreement may potentially enhance our ability to generate globally relevant clinical insights that reflect diverse demographic and disease profiles. Our federated platform enables diverse hospitals in cities such as Singapore, Delhi, Taipei and Tokyo to coordinate research at source, closer to real-time and with high fidelity, all within a secure infrastructure that never moves patient data. When these hospitals implement MSK's data standards, they're opening doors to collaborate with investigators at one of the world's most respected cancer centers."

“MSK is excited to partner with Oncoshot and its network of affiliated hospitals across the Asia-Pacific region. Cancer is a global disease, and advancing care requires a deeper understanding of treatment outcomes across diverse patient populations and healthcare systems. At MSK, we have developed a standardized pan-cancer data model—the Core Cancer Data Elements (CCDE)— which provides an ontology-driven framework for harmonizing and analyzing oncology outcomes data. This collaboration will help us integrate data across countries, support global oncology research and generate insights to improve cancer care worldwide,” said Neil J. Shah, MBBS, Assistant Attending Physician, MSK.

For more information about the MSK iHub business accelerator, see here: "https://www.mskcc.org/commercialization/programs-accelerators/msk-innovation-hub". Commercialization Accelerators & Programs: MSK Innovation Hub | Memorial Sloan Kettering Cancer Center

MSK has financial interests in Oncoshot. 

About Oncoshot

Oncoshot provides a trusted federated AI platform that enables leading cancer centers across Asia-Pacific, Europe and the United States to generate high-quality clinical, genomics, and outcomes data while participating in globally relevant research. With deployments at major cancer centers in APAC and partnerships with major pharmaceutical sponsors, Oncoshot connects 20+ hospitals across 7 countries. The company is headquartered in Singapore with operations across APAC, Europe and the United States. For more information, visit www.oncoshot.com.

Media Contacts: Huren Sivaraj huren@oncoshot.com